Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
Jamil Rivers, 42, is the board president of METAvivor, a nonprofit breast cancer organization. She is living with metastatic breast cancer.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.
With Stand Up To Cancer, he hopes to increase diversity in this field so all patients can benefit equally from potential cancer treatments.
Draft recommendation would ensure more women and Black people meet the screening criteria.
Watch two AIDS experts discuss the links between COVID-19 and HIV—including hydroxychloroquine.
Advocating for yourself is the best medicine.
A cancer diagnosis often means extreme financial stress—and fights with insurance providers.
A new clinical trial addresses a potentially harmful side effect of drug treatment for Black women with breast cancer.
The study raises concerns about the effectiveness of cancer drugs, as genetic differences may affect how someone responds to a drug.
New initiative will help health care providers navigate the process of submitting expanded access requests.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.